Endocyte Bullish on Potential Blockbuster

Posted: Updated:
(image courtesy of Endocyte) Mike Sherman previously served as chief financial officer and helped the company transition to being publicly-traded. (image courtesy of Endocyte) Mike Sherman previously served as chief financial officer and helped the company transition to being publicly-traded.
WEST LAFAYETTE -

The chief executive officer of West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) is using a word to describe the company's $12 million worldwide licensing acquisition of a late-stage prostate cancer therapy that he says is often overused: transformational. "In this case, the word is absolutely fitting," said Mike Sherman during a conference call with investors detailing the deal with Germany-based ABX GmbH. Endocyte has been working to reverse a series of quarterly losses in recent years, including a major restructuring and work force reduction announced in June.

Sherman has an ambitious timeline for PSMA-617, which he says could begin the clinical trial process early next year and complete trial stages as early as 2020. "Our experience with PSMA targeting and companion imaging development, in addition to our relationships with distinguished prostate cancer investigators from around the world, uniquely position Endocyte to lead this therapy to registration," Sherman said in a statement. During Monday's conference call, he added the therapy, if it meets approvals, would position Endocyte in a leading position in a $1 billion prostate cancer-fighting market.

Sherman and Chief Medical Officer Alison Armour say the high potential of the prostate-specific membrane antigen presents a rare opportunity. "Despite advances in the last decade that slow the progression of prostate cancer, once metastasized it is nearly always lethal, leading to 300,000 worldwide deaths annually," said Armour. "177Lu-PSMA-617 has demonstrated the most compelling activity of any drug currently in development for these post-chemotherapy patients."

Aside from a "very targeted" proof-of-concept data effort for the company's CAR T-cell program, Sherman says Endocyte's resources will be focused on developing the promising prostate cancer therapy. Additionally, "we will explore out-licensing opportunities for all other development programs," he said.

Down the line, Sherman says Endocyte has an opportunity to develop a pipeline of similar therapies that target other deadly diseases. He has served in c-level roles with the company for the last 11 years and in mid-2016, succeeded co-founder Ron Ellis as president and CEO.

Mike Sherman has an ambitious timeline for PSMA-617, which he says could begin the clinical trial process early next year and complete trial stages as early as 2020.
  • Perspectives

    • Take Time to Face Reality

      When is the last time that you as a business owner truly stopped for 30 minutes or an hour and truly took some quiet time to reflect on your business? Like most owners, it’s probably been quite some time. We all get busy doing things, working hard, taking care of customers, running the business. But if we don’t take some time each day, week, month or quarter to slow down, we are setting ourselves up for failure. Business leaders and owners need the time to slow down to...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • (Photo Courtesy: Roche Diagnostics)

      Roche VP on List of Influential Women Executives

      An executive with Roche Diagnostics has joined an exclusive list of prominent and influential women, including Oprah Winfrey and Serena Williams.  Cindy Carlisle, Vice President of Human Resources at Roche Indy, was named to Savoy Magazine’s 2019 Most Influential Women in Corporate America. 

    • (Image courtesy of INDOT)

      Noblesville Details Infrastructure Improvement Projects

      The city of Noblesville announced plans for a major infrastructure partnership with the Indiana Department of Transportation that includes five new roundabout intersections. The $16 million total cost of the project will be split with INDOT covering $9.5 million.

    • Shelly Timmons

      IU Health Names New Leader of Neurosurgery

      The Indiana University School of Medicine and IU Health Physicians have named Shelly Timmons to lead the department of neurosurgery. She previously served at Penn State Health Milton S. Hershey Medical Center as vice chair for administration in the department of neurosurgery and director of neurotrauma.  

    • MainGate is headquartered in Indianapolis.

      New York Company to Acquire MainGate

      Indianapolis-based MainGate LLC will soon be under new ownership. New York-based Legends has announced plans to acquire the event retail and merchandise company, though financial terms of the deal are not being disclosed.  MainGate provides custom merchandise marketing services through event retail, team stores and e-commerce platforms. Legends says MainGate will integrate into its hospitality experience division, led by President Dan Smith. The company says it will use the...

    • Image courtesy of the Northeast Indiana Building & Construction Trades Council.

      New Leadership for Skilled Trades Coalition

      A coalition of Allen County educators and businesses which wants to highlight career opportunities for young people in skilled trades is getting a new name and new management. But its mission remains the same. Previously known as the Gateway Coalition, it’s now called the MadeByMe Coalition. As part of the transition, Greater Fort Wayne Inc, that areas’ chamber of commerce, now runs the operation. In an interview with Inside INdiana Business, GFW Chief Executive Officer...